Edition:
United Kingdom

Glenmark Pharmaceuticals Ltd (GLEN.NS)

GLEN.NS on National Stock Exchange of India

453.30INR
16 Jul 2019
Change (% chg)

-- (--)
Prev Close
Rs453.30
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
892,191
52-wk High
Rs711.90
52-wk Low
Rs423.65

Latest Key Developments (Source: Significant Developments)

Glenmark Pharmaceuticals Gets ANDA Approval For Ranolazine Extended-Release Tablets
Tuesday, 9 Jul 2019 

July 9 (Reuters) - Glenmark Pharmaceuticals Ltd ::GETS ANDA APPROVAL FOR RANOLAZINE EXTENDED-RELEASE TABLETS, 500 MG AND 1,000 MG.  Full Article

Glenmark Pharmaceuticals To Partner With Novartis In Brazil
Monday, 24 Jun 2019 

June 24 (Reuters) - Glenmark Pharmaceuticals Ltd ::GLENMARK TO PARTNER WITH NOVARTIS TO PROMOTE, COMMERCIALIZE AND DISTRIBUTE THREE RESPIRATORY PRODUCTS IN BRAZIL.NOVARTIS WILL BE RESPONSIBLE TO MANUFACTURE PRODUCTS AND GLENMARK WILL EXCLUSIVELY COMMERCIALIZE THE PRODUCTS IN BRAZIL.DEAL BETWEEN UNITS GLENMARK FARMACÊUTICA & NOVARTIS BIOSCIENCES FOR 3 RESPIRATORY PRODUCTS.  Full Article

Glenmark Pharmaceuticals Gets ANDA Approval For Clindamycin And Benzoyl Peroxide Gel
Friday, 15 Mar 2019 

March 15 (Reuters) - Glenmark Pharmaceuticals Ltd ::SAYS GETS ANDA APPROVAL FOR CLINDAMYCIN AND BENZOYL PEROXIDE GEL.  Full Article

Glenmark Pharmaceuticals Gets ANDA Approval For Clobetasol Propionate Foam
Monday, 18 Feb 2019 

Feb 18 (Reuters) - Glenmark Pharmaceuticals Ltd ::SAYS RECEIVES ANDA APPROVAL FOR CLOBETASOL PROPIONATE FOAM.  Full Article

India's Glenmark Pharmaceuticals Dec-Qtr Profit Rises
Thursday, 14 Feb 2019 

Feb 14 (Reuters) - Glenmark Pharmaceuticals Ltd ::DEC QUARTER CONSOL PROFIT FROM CONTINUING OPERATIONS 1.16 BILLION RUPEES VERSUS PROFIT OF 1.05 BILLION RUPEES LAST YEAR.CONSENSUS FORECAST FOR DEC QUARTER CONSOL PROFIT WAS 2.28 BILLION RUPEES.DEC QUARTER CONSOL TOTAL REVENUE FROM OPERATIONS 25.55 BILLION RUPEES VERSUS 22.04 BILLION RUPEES LAST YEAR.  Full Article

Glenmark Pharmaceuticals Approves Spin Off Its Innovation Business Into New Company
Thursday, 14 Feb 2019 

Feb 14 (Reuters) - Glenmark Pharmaceuticals Ltd ::GAVE IN-PRINCIPLE APPROVAL TO SPIN OFF INNOVATION BUSINESS INTO A NEW COMPANY IN US.NEW INNOVATION COMPANY WILL FOCUS ON THERAPEUTIC AREAS OF IMMUNOLOGY, ONCOLOGY AND PAIN MANAGEMENT..SAYS NEW INNOVATION COMPANY WILL BE A WHOLLY-OWNED SUBSIDIARY OF GLENMARK AND WILL BE BASED IN THE US..NEW COMPANY WILL HAVE OVER 400 EMPLOYEES AS PART OF THIS BUSINESS.GLENMARK PHARMACEUTICALS - SPECIALTY AND GENERICS BUSINESS WILL CONTINUE TO BE HOUSED IN PARENT CO AND WILL NOT BE PART OF THIS NEW COMPANY.THE NEW INNOVATION CO WILL BE BASED IN U.S. & WILL HAVE INDEPENDENT BOARD AND NEW CEO.  Full Article

Glenmark Pharmaceuticals Gets Tentative ANDA Approval For Fulvestrant Injection
Thursday, 7 Feb 2019 

Feb 7 (Reuters) - Glenmark Pharmaceuticals Ltd ::SAYS CO RECEIVES TENTATIVE ANDA APPROVAL FOR FULVESTRANT INJECTION, 250 MG/5 ML.  Full Article

Glenmark Pharmaceuticals Gets Tentative ANDA Approval For Topiramate Extended-Release Capsules
Thursday, 24 Jan 2019 

Jan 24 (Reuters) - Glenmark Pharmaceuticals Ltd ::SAYS CO GETS TENTATIVE ANDA APPROVAL FOR TOPIRAMATE EXTENDED-RELEASE CAPSULES.  Full Article

Glenmark Pharmaceuticals Enters Into Licensing Agreement With Yuhan Corp
Thursday, 10 Jan 2019 

Jan 10 (Reuters) - Glenmark Pharmaceuticals Ltd ::SAYS ENTERS INTO AN EXCLUSIVE LICENSING AGREEMENT WITH YUHAN CORPORATION.DEAL WITH YUHAN CORP TO COMMERCIALIZE INVESTIGATIONAL SEASONAL ALLERGIC RHINITIS NASAL SPRAY RYALTRIS IN SOUTH KOREA.CO TO BE RESPONSIBLE FOR MANUFACTURING AND SUPPLY OF PRODUCT, WHILE YUHAN WILL BE RESPONSIBLE FOR REGULATORY FILING.CO WILL RECEIVE AN UPFRONT PAYMENT, REGULATORY AND COMMERCIAL MILESTONE PAYMENTS AS WELL AS ROYALTIES FROM YUHAN.  Full Article

Glenmark Pharmaceuticals Gets ANDA Approval For Fluocinolone Acetonide Oil
Tuesday, 18 Dec 2018 

Dec 18 (Reuters) - Glenmark Pharmaceuticals Ltd ::SAYS RECEIVES ANDA APPROVAL FOR FLUOCINOLONE ACETONIDE OIL, 0.01%.  Full Article

Swiss stocks - Factors to watch on June 24

ZURICH/BERLIN, June 24 The Swiss blue-chip SMI was seen opening 0.05 percent lower at 9,918 points on Monday, according to premarket indications by bank Julius Baer .